MedTrace Logo

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

NCT00432237 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1703

Last updated 2015-07-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.

Conditions

Interventions

DRUG

MK0974 50 mg

DRUG

MK0974 150 mg

DRUG

MK0974 300 mg

DRUG

Comparator: Placebo

MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432237 on ClinicalTrials.gov